Estrella Immunopharma Adds Fifth Site to STARLIGHT-1 Trial
Estrella Immunopharma activated Intermountain Health LDS Hospital as the fifth site for its STARLIGHT-1 trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Estrella Immunopharma Adds Fifth Site for Phase I/II EB103 Trial in B — Cell Non — Hodgkin’s Lymphoma
Estrella Immunopharma activated Intermountain Health LDS Hospital as the fifth site for its Phase I/II STARLIGHT-1 trial of EB103. The Salt Lake City hospital is expected to begin screening and enrolling patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma following site initiation. The ongoing expansion